Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease;Parkinson Disease;Dementia, Date of authorisation: 03/12/1998, Revision: 45, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
An Update on Field Alert Reports (FAR) and Biological Product Deviation Reports (BPDR) - 05/24/2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Dementia;Alzheimer Disease;Parkinson Disease, Date of authorisation: 11/05/1998, Revision: 46, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
Human medicines European public assessment report (EPAR): Amversio, betaine anhydrous, Homocystinuria, Date of authorisation: 05/05/2022, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Colitis, Ulcerative, Date of authorisation: 26/05/2023, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
Human medicines European public assessment report (EPAR): Zonisamide Mylan, zonisamide, Epilepsy, Date of authorisation: 31/03/2016, Revision: 9, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-08
FDA Compounding Quality Center of Excellence Cross-Sector Stakeholder Group
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
Tainted Weight Loss Products
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-08 By FDA
Recently Issued Guidance Documents
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-06-07 By FDA
Administrative Guidances
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-06-07 By FDA
What’s New for Biologics
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-06-07 By FDA
Drug Shortages | Additional News and Information
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-07 By FDA
FDA updates on hand sanitizers consumers should not use
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-07 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.